Selective pharmacological inhibition of distinct nitric oxide synthase isoforms

Biochemical Pharmacology

Volumn 51, Issue 4, 1996, Pages 383-394

  Southan, Garry J ^a   Szabó, Csaba ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

7 nitroindazole; amidines; aminoguanidine; endothelium; inflammation; isothioureas; L arginine; macrophage; N(G) nitro L argini ne; nitric oxide; selectivity; sh ock; vascular effects

Indexed keywords

7 NITROINDAZOLE; AMIDINE; AMINOGUANIDINE; ARGININE DERIVATIVE; CALMODULIN; CITRULLINE; EBSELEN; EBSELEN DERIVATIVE; GUANIDINE DERIVATIVE; HOMOARGININE; IMIDAZOLE DERIVATIVE; ISOENZYME; METHYLENE BLUE; N(G) ALLYLARGININE; N(G) AMINOARGININE; N(G) CYCLOPROPYLARGININE; N(G) HYDROXYARGININE; N(G) METHYLARGININE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; N5 (1 IMINOETHYL)ORNITHINE; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PSEUDOTHIOUREA DERIVATIVE; S ETHYLTHIOCITRULLINE; S METHYLTHIOCITRULLINE; TETRAHYDROBIOPTERIN; THIOCITRULLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL MODEL; BRAIN INJURY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INDUCTION; HUMAN; INFLAMMATION; MACROPHAGE; NERVE CELL DEGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SHOCK; STRUCTURE ACTIVITY RELATION; VASCULAR ENDOTHELIUM;

EID: 0030040255     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(95)02099-3     Document Type: Note

References (131)

1. Nathan C, Nitric oxide as a secretory product of mammalian cells. FASEB J 6: 3051-3064, 1992.
2. Marletta MA, Mammalian synthesis of nitrite, nitrate, nitric oxide and N-nitrosating agents. Chem Res Toxicol 1: 249-257, 1988.
3. Marietta MA, Nitric oxide synthase structure and mechanism. J Biol Chem 268: 12231-12234, 1993.
4. Vane JR, The Croonian lecture, 1993: The endothelium: Maestro of the blood circulation. Proc R Soc Lond B 343: 225-246, 1994.
5. Dinerman JL, Lowenstein CJ and Snyder SH, Molecular mechanisms of nitric oxide production. Potential relevance to cardiovascular disease. Circ Res 73: 217-222, 1993.
6. Snyder S and Bredt DS, Biological roles of nitric oxide. Sci Am 166: 28-35, 1992.
7. Dawson VL, Dawson TM, London ED, Bredt DS and Snyder SH, Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 88: 6368-6371, 1991.
8. Garthwaite J, Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci 14: 60-67, 1991.
9. Xie Q and Nathan C, The high-output nitric oxide pathway: Role and regulation. J Leukoc Biol 56: 576-582, 1994.
10. Kilbourn RG and Griffith OW, Overproduction of nitric oxide in cytokine-mediated and septic shock. J Natl Cancer Inst 84: 827-831, 1992.
11. Palmer RMJ, The discovery of nitric oxide in the vessel wall. A unifying concept in the pathogenesis of sepsis. Arch Surg 128: 396-401, 1993.
12. Szabó C and Thiemermann C, Invited opinion: Role of nitric oxide in hemorrhagic, traumatic and anaphylactic shock and in thermal injury. Shock 2: 145-155, 1994.
13. Szabó C, Alterations in nitric oxide production in various forms of circulatory shock. New Horizons 3: 2-32, 1995.
14. McCartney-Francis N, Allen JN, Mizel DE, Albina J, Xie QW, Nathan CF and Wahl SM, Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 178: 749-753, 1993.
15. Miller MJS, Sadowska-Krowicka H, Chotinaruemol S, Kakkis JL and Clark DA, Amelioration of chronic iletis by nitric oxide synthase inhibition. J Pharmacol Exp Ther 264: 11-16, 1993.
16. Chen P, Tsai AL and Wu K, Cysteine 184 of endothelial nitric oxide synthase is involved in heme coordination and catalytic activity. J Biol Chem 269: 25062-25066, 1994.
17. McMillan K and Masters BSS, Prokaryotic expression of the heme- and flavin-binding domains of rat neuronal nitric oxide synthase as distinct polypeptides: Identification of the heme-binding proximal thiolate ligand as cysteine-415. Biochemistry 34: 3686-3693, 1995.
18. Stuehr DJ, Fasehun OA, Kwon NS, Gross SS, Gonzalez JA, Levi R and Nathan CF, Inhibition of macrophage and endothelial cell nitric oxide synthase by diphenyleneiodonium and its analogs. FASEB J 5: 98-103, 1991.
19. Nishimura JS, Martasek P, McMillan K, Salerno J, Liu Q, Gross SS, Masters BSS, Modular structure of neuronal nitric oxide synthase: Localization of the arginine binding site and modulation by pterin. Biochem Biophys Res Commun 210: 288-294, 1995.
20. G-methylarginine requires NADPH-dependent hydroxylation. J Med Chem 36: 491-496, 1993.
21. ω-hydroxy-L-arginine to citrulline and nitric oxide. J Biol Chem 269: 17776-17779, 1995.
22. Fukuto JM and Chaudhuri G, Inhibition of constitutive and inducible nitric oxide synthase. Potential selective inhibition. Annu Rev Pharmacol Toxicol 35: 165-194, 1995.
23. Komori Y, Wallace G and Fukuto J, Inhibition of purified nitric oxide synthase from rat cerebellum and macrophage by L-arginine analogs. Arch Biochem Biophys 315: 213-218, 1994.
24. Yokoi I, Kabuto H, Habu H, Inada K, Toma J and Mori A, Structure-activity relationships of arginine analogues on nitric oxide synthase activity in the rat brain. Neuropharmacology 33: 1261-1265, 1994.
25. G-Monomethyl-L-arginine causes nitric oxide synthesis in isolated arterial rings: Trouble in paradise. Biochem Biophys Res Commun 188: 590-596, 1992.
26. 2+/ calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J 281: 627-630, 1992.
27. Nussler AK, Billiar TR, Liu ZZ and Morris SM, Coinduction of nitric oxide synthase and arginosuccinate synthetase in a murine macrophage cell line. J Biol Chem 269: 1257-1261, 1994.
28. + mediated L-arginine transport by an inflammatory agent. Surgery 112: 403-411, 1992.
29. Schott CA, Vetrovsky P and Stoclet JC, Cationic amino acids inhibit the effects of L-arginine in rat aorta exposed to lipopolysaccharide. Eur J Pharmacol 236: 155-157, 1993.
30. Bogle RG, Moncada S, Pearson JD and Mann GE, Identification of inhibitors of nitric oxide synthase that do not interact with the endothelial cell L-arginine transporter. Br J Pharmacol 105: 768-770, 1992.
31. Griffith OW, Park KH, Aisaka K, Levi R and Gross SS, The role of plasma arginine in nitric oxide synthesis: Studies with arginase-treated guinea pigs and rats. In: The Biology of Nitric Oxide. I. Physiological and Clinical Aspects (Eds. Moncada S, Marietta MA, Hibbs JB and Higgs EA), pp. 6-9. Portland Press, London, 1992.
32. Bianchi M, Bloom O, Meistrell M, Ulrich A, Cerami A and Tracey KJ, Development of a selective inhibitor of cytokine-inducible L-arginine transport (CNI-1493) that blocks macrophage production of NO and TNFα and protects against LPS lethality. Shock 3(Suppl 2): 9, 1995.
33. Schini VB and Vanhoutte PM, Inhibitors of calmodulin impair the constitutive but not the inducible nitric oxide synthase activity in the rat aorta. J Pharmacol Exp Ther 261: 553-559, 1992.
34. Jorens PG, Overveld FJ, Bult H, Vermeire PA and Herman AG, Pterins inhibit nitric oxide synthase activity in rat alveolar macrophages. Br J Pharmacol 107: 1088-1091, 1992.
35. Gross SS and Levi R, Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem 267: 25722-25729, 1992.
36. Schoedon G, Blau N, Schneemann M, Flury G and Schaffner A, Nitric oxide production depends on preceding tetrahydrobiopterin synthesis by endothelial cells: Selective suppression of induced nitric oxide production by sepiapterin reductase inhibitors. Biochem Biophys Res Commun 199: 504-510, 1994.
37. Klemm P, Ostrowski J, Morath T, Gruber C, Martorana PA and Henning R, N-Acetylserotonin prevents the hypotension induced by bacterial lipopolysaccharides in the rat. Eur J Pharmacol 250: R9-R10, 1993.
38. Klemm P, Hecker M, Stockhausen H, Wu CC and Thiemermann C, Inhibition by N-acetyl-5-hydroxytryptamine of nitric oxide synthase expression in cultured cells and in the anaesthetized rat. Br J Pharmocol 115: 1175-1181, 1995.
39. Levine RA, Miller LP and Lovenberg W, Tetrahydrobiopterin in striatum: Localization in dopamine nerve terminals and role in catecholamine synthesis. Science 214: 919-921, 1981.
40. Zimmerman TP, Nichol CA and Viveros OH, Regulation of guanosine triphosphate cyclohydrolase and tetrahydrobiopterin levels and the role of the cofactor in tyrosine hydroxylation in primary cultures of adrenomedullary chromaffin cells. J Neurochem 46: 1190-1199, 1986.
41. Kapatos G, Hirayama K and Hasegawa H, Tetrahydrobiopterin turnover in cultured rat sympathetic neurons: Developmental profile, pharmacologic sensitivity, and relationship to norepinephrine synthesis. J Neurochem 59: 2048-2055, 1992.
42. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl G and Snyder S, Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA 90: 9808-9812, 1993.
43. Moncada S, Palmer RMJ and Higgs EA, Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 43: 109-141, 1991.
44. G-nitro-arginine on endothelium-dependent relaxation of rat aorta. J Pharmacol Exp Ther 265: 112-119, 1993.
45. G-nitro-L-arginine act as prodrugs in their inhibition of inducible nitric oxide syntase. In: The Biology of Nitric Oxide. 4: Enzymology, Biochemistry and Immunology (Eds. Moncada S, Feelisch M, Busse R and Higgs EA), pp. 4-7. Portland Press, London, 1995.
46. Lambert LE, French JF, Whitten JP, Baron BM and McDonald IA, Characterization of cell selectivity of two novel inhibitors of nitric oxide synthesis. Eur J Pharmacol 216: 131-134, 1992.
47. Gross SS, Jaffe EA, Levi R and Kilbourn RG, Cytokine-activated endothelial cells express an isotype of nitric oxide synthase which is tetrahydrobiopterin-dependent, calmodulin-independent and inhibited by arginine analogs with a rank-order of potency characteristic of activated macrophages. Biochem Biophys Res Commun 187: 823-829, 1991.
48. Lambert LE, Whitten JP, Baron BM, Cheng HC, Doherty NS and McDonald IA, Nitric oxide synthesis in the CNS, endothelium and macrophages differs in its sensitivity to inhibition by arginine analogues. Life Sci 48: 69-75, 1991.
49. G-methylarginine. Biochem Biophys Res Commun 170: 96-103, 1990.
50. G-nitro-arginine. Biochemistry 32: 8512-8517, 1993.
51. Abu-Soud H, Feldman P, Clark P and Stuehr D, Electron transfer in the nitric-oxide synthases. J Biol Chem 269: 32318-32326, 1994.
52. McCall TB, Feelisch M, Palmer RMJ and Moncada S, Identification of N-iminoethyl-L-ornithine as an irreversible inhibitor of nitric oxide synthase in phagocytic cells. Br J Pharmacol 102: 234-238, 1991.
53. G-methyl-L-arginine: Evidence for heme loss. Biochemistry 33: 14784-14791, 1994.
54. Klatt P, Schmidt K, Brunner F and Mayer B, Inhibitors of brain nitric oxide synthase: Binding kinetics, metabolism and enzyme inactivation. J Biol Chem 269: 1674-1680, 1994.
55. Vallance P, Leone A, Calver A, Collier J and Moncada S, Accumulation of endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 393: 575-577, 1992.
56. MacAllister RJ, Whitley GS and Vallance P, Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int 45: 737-742, 1994.
57. Yu XJ, Li YJ and Xong Y, Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits. Life Sci 54: 753-758, 1994.
58. Stefanovic-Racic M, Stadler J and Evans CH, Nitric oxide and arthritis. Arthritis Rheu 36: 1036-1044, 1993.
59. Nava E, Palmer RMJ and Moncada S, Inhibition of nitric oxide synthesis in septic shock: How much is beneficial? Lancet 338: 1555-1557, 1991.
60. G-monomethyl-L-arginine. J Cardiovasc Pharmacol 20(Suppl 12): S132-S134, 1992.
61. Lukic ML, Stosic-Grujicic S, Ostojic N, Chan WL and Liew FY, Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. Biochem Biophys Res Commun 178: 913-920, 1991.
62. Kolb H, Kiesel U, Kroncke KD and Bachofen V, Suppression of low dose streptozocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor. Life Sci 49: PL213-PL217, 1991.
63. Meyer J, Traber LD, Nelson S, Lentz CW, Nakazawa H, Herndon DN, Noda H and Traber DL, Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol 73: 324-328, 1992.
64. Laszlo F, Whittle BJR and Moncada S, Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br J Pharmacol 111: 1309-1315, 1994.
65. Szabó C, Southan GJ and Thiemermann C, Beneficial effects and improved survival in rodent models of septic shock with S-methyl-isothiourea sulfate, a novel, potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 91: 12472-12476, 1994.
66. MacMicking JD, Nathan C, Horn G, Chartrain N, Fletcher DS, Trumbauer M, Stevens K, Xie Q-W, Sokol K, Hutchinson N, Chen H and Mudgett JS, Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 81: 641-650, 1995.
67. G-monomethyl-L-arginine inhibits endotoxin-induced nitrite/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol 48: 565-569, 1990.
68. Robertson CA, Green BG, Niedzwiecki L, Harrison L and Grant SK, Effect of nitric oxide synthase inhibitors on rat liver arginase. Biochem Biophys Res Commun 197: 523-528, 1993.
69. Frew JD, Paisley K and Martin W, Selective inhibition of basal but not agonist-stimulated activity of nitric oxide in rat aorta by NG-monomethyl-L-arginine. Br J Pharmacol 110: 1003-1008, 1993.
70. Buxton ILO, Cheek DJ, Eckman D, Westfall DP, Sanders KM and Keef KD, NG-Nitro-L-arginine methyl ester and other alkyl esters of arginine are muscarinic receptor antagonists. Circ Res 72: 387-395, 1993.
71. ω-nitro-L-arginine methylester attenuates brain catalase activity in vitro. Life Sci 56: 1321-1324, 1995.
72. Peterson DA, Peterson DC, Archer S and Weir EK, The non-specificity of specific nitric oxide synthase inhibitors. Biochem Biophys Res Commun 187: 797-801, 1992.
73. ω-Amino-L-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J Exp Med 176: 1175-1182, 1992.
74. Furfine ES, Harmon MF, Paith JE, Knowles RG, Salter M, Kiff RJ, Duffy C, Hazelwood R, Oplinger JA and Garvey EP, Potent and selective inhibition of human nitric oxide synthases. Selective inhibition of neuronal nitric oxide synthase by S-methyl-L-thiocitrulline and S-ethyl-L-thiocitrulline. J Biol Chem 269: 26677-26683, 1994.
75. Narayanan K and Griffith O, Synthesis of L-thiocitrulline, L-homothiocitrulline, and S-methyl-L-thiocitrulline: A new class of potent nitric oxide synthase inhibitors. J Med Chem 37: 885-887, 1994.
76. 6-(1-Iminoethyl)lysine: A selective inhibitor of inducible nitric oxide synthase. J Med Chem 37: 3886-3888, 1994.
77. Frey C, Narayanan K, McMillan K, Spack L, Gross S, Masters B and Griffith O, L-Thiocitrulline. A stereospecific, heme-binding inhibitor of nitric-oxide synthases. J Biol Chem 269: 26083-26091, 1994.
78. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, Tjoeng FS and Currie MG, Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 273: 15-24, 1995.
79. Wolff DJ, Datto GA, Samatowitz RA and Tempsick RA, Calmodulin-dependent nitric oxide synthase. Mechanism of inhibition by imidazole and phenylimidazoles. J Biol Chem 268: 9425-9429, 1993.
80. Wolff DJ, Lubeskie A and Umansky C, The inhibition of the constitutive bovine endothelial nitric oxide synthase by imidazole and indazole agents. Arch Biochem Biophys 314: 360-366, 1994.
81. Moore PK, Wallace P, Gaffen Z, Hart SL and Babbedge RC, Characterization of the novel nitric oxide synthase inhibitor 7-nitro indazole and related indazoles: Antinociceptive and cardiovascular effects. Br J Pharmacol 110: 219-224, 1993.
82. Hasan K, Heesen BJ, Corbett JA, McDaniel ML, Chang K, Allison W, Wolfenbuttel BHR, Williamson JR and Tilton RG, Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 249: 101-106, 1993.
83. Sup SJ, Green BG and Grant SK, 2-Iminobiotin is an inhibitor of nitric oxide synthases. Biochem Biophys Res Commun 204: 962-968, 1994.
84. Hatchett RJ, Gryglewski RJ, Mlochowski J, Zembowicz A and Radziszewski W, Carboxyebselen a potent and selective inhibitor of endothelial nitric oxide synthase. J Physiol Pharmacol 45: 55-67, 1994.
85. Yokoi I, Kabuto H, Habu H and Mori A, α-Guanidino-glutaric acid, an endogenous convulsant, as a novel nitric oxide synthase inhibitor. J Neurochem 63: 1565-1567, 1994.
86. Chiesi M and Schwaller R, Inhibition of constitutive endothelial NO synthase activity by tannin and quercetin. Biochem Pharmacol 49: 495-501, 1995.
87. Buchmuller-Rouiller Y, Schneider P, Betz-Corradin S, Smith J and Mauél, 3-Amino-1,2,4-triazole inhibits macrophage NO synthase. Biochem Biophys Res Commun 183: 150-155, 1992.
88. Osawa Y and Davila J, Phencyclidine, a psychotomimetic agent and drug of abuse, is a suicide inhibitor of brain nitric oxide synthase. Biochem Biophys Res Commun 194: 1435-1439, 1993.
89. Mayer B, Brunner F and Schmidt B, Inhibition of nitric oxide synthesis by methylene blue. Biochem Pharmacol 45: 367-374, 1993.
90. Corbett A, Tilton RG and Chang K, Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 41: 552-556, 1992.
91. Wu C-C, Chen S-J, Szabó C, Thiemermann C and Vane JR, Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br J Pharmacol 114: 1666-1672, 1995.
92. G-nitro-L-arginine and aminoguanidine on constitutive and inducible nitric oxide synthase in rat aorta. Biochem Biophys Res Commun 199: 147-154, 1994.
93. Laszlo F, Evans SM and Whittle BJR, Aminoguanidine inhibits both constitutive and inducible nitric oxide synthase isoforms in rat intestinal microvasculature in vivo. Eur J Pharmacol 272: 169-175, 1994.
94. G-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 44: 360-364, 1995.
95. Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL and Tilton RG, Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 93: 2684-2690, 1994.
96. Misko TP, Moore WM, Kasten TP, Nickols DA, Corbett JA, Tilton RG, McDaniel ML, Williamson JR and Currie MG, Selective inhibition of the inducible NO synthase by aminoguanidine. Eur J Pharmacol 233: 119-125, 1993.
97. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML and Williamson JR, Prevention of diabetic vascular dysfunction by guanidines. Inhibition of nitric oxide synthase versus advanced glycation end-product formation. Diabetes 42: 221-232, 1993.
98. Holstad M and Sandler S, Aminoguanidine, an inhibitor of nitric oxide formation, fails to protect against insulitis and hyperglycemia induced by multiple low dose streptozotocin injections in mice. Autoimmunity 15: 311-314, 1993.
99. Griffiths MJ, Messent M, MacAllister RJ and Evans TW, Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 110: 963-968, 1993.
100. Lomis TJ, Siffring CW, Chalasani S, Ziegler DW, Lentz KE, Stauffer KE, McMillan A, Agarwal N, Lowenstein CJ and Rhoads JE Jr, Nitric oxide synthase inhibitors N-monomethyl-arginine and aminoguanidine prevent the progressive and severe hypotension associated with a rat model of pancreatitis. Am Surg 61: 7-10, 1995.
101. Arkowitz M, Szabó C, Wispe JR and Garcia VF, Selective inhibition of the inducible isoform of nitric oxide synthase inhibits endotoxin-induced pulmonary leak. J Pediatr Surg, in press.
102. Bieganski T, Kusche J, Lorenz W, Hesterberg R, Stahlknecht CD and Feussner KD, Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism. Biochem Biophys Acta 756: 196-203, 1983.
103. Seiler N, Bolkenius FN and Knodgen B, The influence of catabolic reactions on polyamine excretion. Biochem J 225: 219-226, 1985.
104. Ou P and Wolff SP, Aminoguanidine: A drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharmacol 46: 1139-1144, 1993.
105. Picard S, Parthasarathy S, Fruebis J and Witztum JL, Aminoguanidine inhibits oxidative modification of low density lipoprotein protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 89: 6876-6880, 1992.
106. Eaton JD, Stevens EJ and Tomlinson DR, Effects of aminoguanidine on prostacyclin release and interactions with L-NAME. Br J Pharmacol 106: P8, 1992.
107. Wolff DJ and Lubeskie A, Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys 316: 290-301, 1995.
108. Southan GJ, Salzman AL and Szabó C, Merkaptoalkyle guanidines: A novel class of inhibitors of the inducible isoform of nitric oxide synthase. FASEB J 8: A28, 1995.
109. Garvey EP, Oplinger JA, Tanoury GJ, Sherman PA, Fowler M, Marshall S, Harmon MF, Patih JE and Furfine ES, Potent and selective inhibition of human nitric oxide synthases. J Biol Chem 269: 26669-26676, 1994.
110. Southan GJ, Szabó C and Thiemermann C, Isothioureas: Potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol 114: 510-516, 1995.
111. Thiemermann C, Rutten H, Wu CC and Vane JR, Nitric oxide and organ failure. Shock 3(Suppl 1): S35, 1995.
112. Kozak A and Arient M, Metabolism and radioprotective effect of AET and MEG in organism. Strahlentherapie 146: 367-373, 1973.
113. Shapira R, Doherty DG and Burnett WT, Chemical protection against ionizing radiation. III. Mercaptoalkylguanidines and related isothiouronium compounds with protective activity. Radiat Res 7: 22-34, 1957.
114. Liebmann J, DeLuca AM, Coffin D, Keefer LK, Venzon D, Wink DA and Mitchell JB, In vivo radiation protection by nitric oxide modulation. Cancer Res 54: 3365-3368, 1994.
115. +-ATPase. J Biol Chem 267: 1141-1149, 1992.
116. Fastier FN and Smirk F, Circulatory properties of iso-thioureas, guanidines, iso-ureas and amidines. J Pharmacol 89: 256-270, 1947.
117. Fastier FN, Structure-activity relationships of amidine derivatives. Pharmacol Rev 14: 37-90, 1962.
118. Ozawa H and Sugawara K, Structure-activity relationships of alkylguanidines on smooth muscle organs. Chem Pharm Bull (Tokyo) 16: 2376-2382, 1968.
119. Kengatharan M, Szabó C, DeKimpe S, Southan GJ and Thiemermann C, S-methyl-isothiourea, a potent inhibitor of the inducible isoform of nitric oxide synthase, has beneficial hemodynamic effects in gram positive and gram negative forms of circulatory shock. FASEB J 8: A28, 1995.
120. Booke M, Schenarts PJ, Shin C, Biondo N, McGuire R, Traber LD and Traber DL, A new non-amino acid inhibitor of nitric oxide synthase (3936W920) in hyperdynamic ovine sepsis. Shock 3(Suppl 1): S72, 1995.
121. Smirk FH and McGeorge M, S-Methylisothiourea sulphate for maintaining blood-pressure in spinal anaesthesia. Lancet 2: 301-302, 1942.
122. Fastier FN and Smirk FH, The circulatory effects of some isothiourea derivatives, with special reference to the sensitization of animals. J Physiol (Lond) 101: 379-388, 1943.
123. Southan GJ, Szabó C, O'Connor MP, Salzman AL and Thiemermann C, Amidines are potent inhibitors of nitric oxide synthases: Preferential inhibition of the inducible isoform. Eur J Pharmacol, in press.
124. Babbedge RC, Bland-Ward PA, Hart SL and Moore PK, Inhibition of rat cerebellar nitric oxide synthase by 7-nitroindazole and related substituted indazoles. Br J Pharmacol 110: 225-228, 1993.
125. Mayer B, Klatt P, Werner ER and Schmidt K, Molecular mechanisms of inhibition of porcine brain nitric oxide synthase by the antinociceptive drug 7-nitro-indazole. Neuropharmacology 33: 1253-1259, 1994.
126. Kovach AGB, Lohinai Z, Balla I, Marczis J, Dombovary Z, Reivich M, Dawson TM and Synder SH, Effect of 7-nitro indazole on rCBF, cerebral NOS catalytic activity and NO content measured by microelectrode. Endothelium 1: S54, 1993.
127. Yoshida T, Limmroth V, Irikura K and Moskowitz MA, The NOS inhibitor, 7-nitroindazole, decreases focal infarct volume but not the response to topical acetylcholine in pial vessels. J Cereb Blood Flow Metab 14: 924-929, 1994.
128. Schulz JB, Matthews RT, Muqit MM, Browne SE and Beal MF, Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 64: 936-939, 1995.
129. Medhurst AD, Greenlees C, Parsons AA and Smith SJ, Nitric oxide synthase inhibitors 7- and 6-nitroindazole relax smooth muscle in vitro. Eur J Pharmacol 256: R5-R6, 1994.
130. Kajekar R, Moore PK and Brain SD, Essential role for nitric oxide in neurogenic inflammation in rat cutaneous microcirculation. Evidence for an endothelium-independent mechanism. Circ Res 76: 441-447, 1995.
131. Hansen OW, Peterson KB, Trivedi M, Moore WM, Currie MG, Manning PT, Connor JR and Pitzele BS, Homopiperidine amidines as selective inhibitors of inducible nitric oxide synthase. Endothelium 3: (Suppl.) S80, 1995.